Chez Smile Blog

¡¡¡Á¤¹¤ß¤ì¤ÎÉÔ°é¾É¹îÉþ¥×¥í¥¸¥§¥¯¥È¡Á
¡¡¤Ï¤¸¤á¤Æ¤³¤Î¥µ¥¤¥È¤òΩ¤Á¾å¤²¤Æ¤«¤é£±£°Ç¯
¡¡¤Þ¤À¤Þ¤À¤´Í÷¤Ë¤Ê¤é¤ì¤ëÊý¤â¿¤¯¤¤¤é¤Ã¤·¤ã¤ë¤è¤¦¤Ç¤¹¤Î¤Ç¡¢
¡¡blogÈǤ˽缡°Ü¹Ô¤ò¿Þ¤Ã¤Æ¤¤¤³¤¦¤È»×¤Ã¤Æ¤¤¤Þ¤¹¡£

 
ÉÔ°é¾É¿ÇÎŤκǶá¤Î¿ÊÊâ
¡Ú»²¹Íʸ¸¥¡Û
¡Ö»ºÉؿͲʼ£Îšס¡¡Ê±Ê°æ½ñŹ¡Ë¡¡Vol. 83, 2001 p.41-44

À¸¿£°å³Ø¤Î¿ÊÊâ¤ÈÀ¸¿£°åÎŤθ³¦

¡¡ÉÔ°é¾É¿ÇÎŤκǶá¤Î¿ÊÊâ
¡¡ Recent progress in the management of recurrent pregnancy losses

¡¡Å쳤Âç³Ø°å³ØÉôÊì»ÒÀ¸°é³Ø·Ï»ºÉؿͲʳØÉôÌç
¡¡ËÒÌî¹±µ×¶µ¼ø¡¡¡¡¿ù¡¡½Óδ¹Ö»Õ


--------------------------------------------------------------------------------

Summary
¡¡ÉÔ°é¾É¤ÎʬÌî¤ÏºÇ¶áÌܳФޤ·¤¤¿ÊÊâ¤ò¿ë¤²¤Æ¤¤¤ë¡£¤½¤Î·ë²Ì¡¢°ÊÁ°¤Ï¸¶°øÉÔÌÀ¤Ç¤¢¤Ã¤¿Æñ¼£À­½¬´·Î®»º¤Î´µ¼Ô¤Î¿¤¯¤Î¿ÇÃÇ¡¢¼£ÎŤ¬²Äǽ¤È¤Ê¤ê¤Ä¤Ä¤¢¤ë¡£Æäˡ¢¹³¥ê¥ó»é¼Á¹³Âξɸõ·²¤ò»Ï¤á¤È¤·¤¿À¸¿£Ìȱֳؤȷì±Õ¶Å¸Ç³Ø¤Ë¤Þ¤¿¤¬¤ëʬÌµÓ¸÷¤òÍá¤Ó¡¢·ì±Õ¡¢¥ê¥¦¥Þ¥Á¡¢Ìȱ֡¢À¸¿£¤Ê¤É¿¤¯¤ÎʬÌî¤ÎÀìÌç²È¤¬³ØºÝŪ¤Ë¸¦µæ¤ò¿Ê¤á¡¢º£Æü¤ÎÉÔ°é¾É¤Î¿ÊÊ⤬¤¢¤ë¤È¸À¤¨¤ë¡£ËܹƤǤϺǶá¤ÎÉÔ°é¾É´ÉÍý¤Î¿·¤·¤¤³µÇ°¤Ë¤Ä¤¤¤Æ²òÀ⤹¤ë¡£


¤Ï¤¸¤á¤Ë
»ÒµÜ¤Ïº£¤À¤Ë¥Ö¥é¥Ã¥¯¥Ü¥Ã¥¯¥¹¤Ç¤¢¤ê¡¢Ãå¾²¤«¤éÇ¥¿±¡¢Ê¬Êڤ˻ê¤ë¤Þ¤Çutero-placental unit¤Ç²¿¤¬µ¯¤­¤Æ¤¤¤ë¤Î¤«ÉÔÌÀ¤ÎÅÀ¤¬Â¿¤¤¡£¤½¤ì¤Ë¤â¤«¤«¤ï¤é¤ºÉÔ°é¾É¤ÎʬÌî¤ÏºÇ¶á10ǯ¤ÇÂ礤¤Ê¤ëȯŸ¤ò¿ë¤²¤Æ¤­¤¿¡£¤½¤ÎÆâÍƤϡ¢À¸¿£Ìȱ֡¢·ì±Õ¶Å¸Ç³Ø¤Î¿ÊÊâ¤Ë°Í¤ë¤È¤³¤í¤¬Â¿¤¯¡¢¹âÅÙ¤ËÀìÌç²½¤·¤Ä¤Ä¤¢¤ë¡£ËܹƤǤϡ¢ÉÔ°é¾É¤Ë¤Ä¤¤¤Æ³µÀ⤷¡¢¤µ¤é¤Ë¤ÏºÇÀèü¤ÎÃθ«¤Ê¤É¤âÊ»¤»¤Æ¾Ò²ð¤·¤¿¤¤¡£

ÉÔ°é¾É¡¢½¬´·Î®»º¤È¤Ï
¡¡"ÉÔ°é¾É"¤È¤Ï¡¢¸·Ì©¤ÊÄêµÁ¤ò¤â¤Ä°å³ØÍѸì¤Ç¤Ï¤Ê¤¤¡£¶¯¤¤¤ÆÄêµÁÉÕ¤±¤ì¤Ð¡¢À®Î©¤·¤¿Ç¥¿±¤ò´°¿ë¤Ç¤­¤º¡¢·ò¹¯¤ÊÀ¸»ù¤Ë·Ã¤Þ¤ì¤Ê¤¤¾ÉÎã¤ò»Ø¤¹¤â¤Î¤È¤¤¤¨¤ë¡£°ìÈÌŪ¤Ë¤Ï½¬´·Î®»º¤ò»Ø¤¹¤³¤È¤¬Â¿¤¤¤¬¡¢Æ±µÁ¤Ç¤Ï¤Ê¤¤¡£½¬´·Î®»º¤È¤Ï¡¢£³²ó°Ê¾åή»º¤ò·«¤êÊÖ¤¹¤³¤È¤Ç¤¢¤ê¡¢»þ´ü¤ÏÇ¥¿±£²£²½µÌ¤Ëþ¤Ë¸ÂÄꤵ¤ì¤ë¡£¤·¤«¤·¤Ê¤¬¤é¡¢ÉÔ°é¾É¤È¸À¤Ã¤¿¾ì¹ç¤ÏÇ¥¿±Ãæ´ü°Ê¹ß¤Î»ÒµÜÆâÂÛ»ù»àË´¤äÈ¿Éüή»º¡Êή»º²ó¿ô£²²ó¡Ë¤â´Þ¤Þ¤ìÆÀ¤ë¡£ÉÔ°é¾É¤ËÁêÅö¤¹¤ë±Ñ¸ì¤È¤·¤Æ¤Ï¡¢recurrent fetal loss¤È¤¤¤¦É½¸½¤ò¤·¤Ð¤·¤ÐÌܤˤ¹¤ë¤¬¡¢fetus¡ÊÂÛ»ù¡Ë¤È¤¤¤¦Ì¾¾Î¤ÏÇ¥¿±£±£°½µ°Ê¸å¤Ë¸ÂÄꤵ¤ì¡¢¤½¤ì°ÊÁ°¤Îembryo¡ÊÂÛ²ê¡Ë¤¬´Þ¤Þ¤ì¤Ê¤¤¤Î¤Ç¡¢recurrent pregnancy loss¤¬Å¬Åö¤Ç¤¢¤ë¤È»×¤ï¤ì¤ë¡£
¡¡°ì²ó¤ÎÆÈΩ¤·¤¿Î®»º¤ÎÉÑÅÙ¤ÏÅý·×¾åÌó£±£µ-£²£°¡ó¤Ç¤¢¤ê¡¢·è¤·¤ÆÄÁ¤·¤¯¤Ê¤¤¡£¤½¤ÎÌ󣶣°-£·£°¡ó°Ê¾å¤ÏÂÛ»ù¤ËÀ÷¿§Âΰ۾郎¤¢¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¢¼õÀºÍñ¤ÎÌó£´£°¡ó¤ËÀ÷¿§Âΰ۾郎¤¢¤ê¡¢¤½¤ì¤¬½ÐÀ¸»þ¤Ë¤Ï£°.£¶¡ó¤Ë¸º¾¯¤¹¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢¤â¤·Î®»º¤È¤¤¤¦¼«Á³ÅñÂÁ¤¬¤ª¤³¤é¤Ê¤±¤ì¤Ð¡¢½ÐÀ¸¤·¤¿»ù¤Î£´£°¡ó¤¬À÷¿§Âΰ۾ï¤ò¤â¤Ä¤³¤È¤Ë¤Ê¤ë1)¡£¤·¤¿¤¬¤Ã¤Æ¤¢¤ë°ÕÌ£¤Ç¤Ï¡¢Î®»º¤Î¿¤¯¤ÏÉÂŪ¤Ç¤Ï¤Ê¤¯¡¢¤½¤ì¤ò»ß¤á¤ë¤³¤È¤â¤Ç¤­¤Ê¤¤¤·¡¢»ß¤á¤ëɬÍפâ̵¤¤¤È¤¤¤¦¤³¤È¤Ë¤Ê¤ë¡£°ì²ó¤äÆó²ó¤Îή»º´û±ý¤¬¤¢¤Ã¤Æ¤â¡¢¤½¤ì¤¬Ä¾¤Á¤ËÉÂŪ¤Ç¤¢¤ê¡¢ÉÔ°é¾É¤Ç¤¢¤ë¤È¤¤¤¦¤³¤È¤Ë¤Ï¤Ê¤é¤Ê¤¤¡£¤Á¤Ê¤ß¤Ë¡¢°ì²ó¤ÎÆÈΩ¤·¤¿Ç¥¿±¤Îή»º¤ÎÉÑÅÙ¤ò£²£°¡ó¤È²¾Äꤹ¤ë¤È¡¢£²²óÈ¿Éüή»ºÎ¨¤Ï0.2¡ß0.2=0.04¤Ç£´¡ó¡¢£³²ó½¬´·Î®»ºÎ¨¤Ï0.04¡ß0.2=0.008¤Ç0.8¡ó¤È¤Ê¤ë¡£¤·¤¿¤¬¤Ã¤Æ¡¢£²²óÈ¿Éüή»º¤Î¾ì¹ç¤ÏÉÂŪ¸¶°ø¤ò¤â¤¿¤º¡¢ÉÔ°é¾É¤È¤Ï¸À¤¨¤Ê¤¤¾ì¹ç¤â¿¤¤¤¬¡¢£³²ó°Ê¾å¼«Á³Î®»º¤ò·«¤êÊÖ¤·¤¿½¬´·Î®»º¤Î¾ì¹ç¤Ï¼«Á³ÅñÂÁ¤È¤¤¤¦¹Í¤¨¤Ç¤Ï³ÎΨŪ¤ËÀâÌÀ¤Ç¤­¤º¡¢ÉÔ°é¾É¤Î¸¶°ø¤ò¸¡º÷¤¹¤ë»ö¤Ë¤Ê¤ë¡£

£±¡¥.ÆâʬÈç°Û¾ï¤ÈÉÔ°é¾É¤Ë´Ø¤¹¤ëºÇ¶á¤Î³µÇ°
¡¡ÉÔ°é¾É¤Î´µ¼Ô¤ËÂФ·¤ÆÆâʬÈç·Ï¤Î¸¡ºº¤ò»Ü¹Ô¤·¡¢²¿¤«°Û¾ï¤¬¸«¤¤½Ð¤µ¤ì¤ì¤Ð¤½¤ì¤¬¸¶°ø¤Ç¤¢¤ë¤È¿ÇÃǤ·¤Æ¼£ÎŤ¹¤ë¤³¤È¤ÏÈó¾ï¤Ë´ðËÜŪ¤Ê»ö¤Ç¤¢¤ë¤È°ìÈ̤ˤϹͤ¨¤é¤ì¤Æ¤¤¤ë¡£¤·¤«¤·¤Ê¤¬¤é¡¢°Õ³°¤Ë¤âÆâʬÈç°Û¾ï¤¬ËÜÅö¤Ëή»º¤Î¸¶°ø¤Ë¤Ê¤êÆÀ¤ë¤Î¤«¾ÚÌÀ¤µ¤ì¤Æ¤¤¤Ê¤¤»ö¤¬Â¿¤¤¡£°Ê²¼¤Ë¡¢ÂåɽŪÆâʬÈç°Û¾ï¤Ë¤Ä¤¤¤ÆÉÔ°é¾É¤È¤Î´Ø·¸¤ò³µÀ⤹¤ë¡£

£±¡Ë²«Âε¡Ç½ÉÔÁ´
¡¡²«Âε¡Ç½ÉÔÁ´¤Ï¥×¥í¥²¥¹¥Æ¥í¥ó·ç˳¤òÍ褷¡¢¤½¤Î·ë²ÌÈ¿Éüή»º¤Î¸¶°ø¤È¤Ê¤êÆÀ¤ë¤¬¡¢Â¿¤¯¤Î¾ì¹ç¤ÏÇ¥¿±Ãæ¤Î¥×¥í¥²¥¹¥Æ¥í¥ó¤Î·ç˳¤Ï¾¤Î¸¶°ø¤Ëµ¯°ø¤¹¤ëή»º¤ÎɬÁ³Åª¡¢Æó¼¡Åª·ë²Ì¤È¹Í¤¨¤é¤ì¤ë¡£ÉÔ°é¾É´µ¼Ô¤Ë¤ª¤±¤ë²«Âε¡Ç½ÉÔÁ´¤ÎÉÑÅ٤ϣ²£°¡Á£¶£°¡ó¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë¤¬¡¢¤³¤ì¤é¤ÏÈóÇ¥¿±»þ¤ÎÏäǤ¢¤Ã¤Æ¡¢¤¹¤Ç¤ËÇ¥¿±¤·¤¿´µ¼Ô¤Ç¤Î²«Âε¡Ç½¤òɾ²Á¤·ÆÀ¤ë¿®Íê¤Ç¤­¤ëÊýË¡¤Ï¸ºß¤·¤Ê¤¤¡£Ç¥¿±»þ¤Î²«ÂΤÏÈóÇ¥¿±»þ¤Î²«ÂΤȤϰۤʤë¤Î¤Ç¡¢ÈóÇ¥¿±¥µ¥¤¥¯¥ë¤Ç¤Î²«Âε¡Ç½¤Îɾ²Á¤ÏÇ¥¿±»þ¤òÈ¿±Ç¤·¤Ê¤¤¤È¤¤¤ï¤ì¤Æ¤¤¤ë¡£½é´üή»º¤Ë½ª¤ï¤Ã¤¿Ç¥¿±¼þ´ü¤ÎÃå¾²Á°´ü¤Î²«ÂÎ¥Û¥ë¥â¥óÃͤϡ¢Ç¥¿±À®¸ù»þ¤ÈÈæ¤Ù¤Æº¹¤¬Ç§¤á¤é¤ì¤Ê¤«¤Ã¤¿¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¢ÉÔ°é¾É´µ¼Ô¤ÎÈóÇ¥¿±¼þ´ü¤Î¹â²¹´üÃæ´Ö¤Ç¤Î·ìÀ¶¥×¥í¥²¥¹¥Æ¥í¥óÃͤòɾ²Á¤·¡¢²«Âε¡Ç½ÉÔÁ´¤Î¤¢¤ë·²¤È¤Ê¤¤·²¤Ëʬ¤±¤Æ¼¡²óÇ¥¿±¤Îή»ºÎ¨¤òÈæ³Ó¤·¤¿¤È¤³¤í¡¢Î¾·²¤Ëº¹¤òǧ¤á¤Ê¤«¤Ã¤¿¤È¤¤¤¦Êó¹ð¤â¤¢¤ë¡£°Ê¾å¤ÎÍͤ˲«Âε¡Ç½ÉÔÁ´¤¬Î®»º¤Î¸¶°ø¤Ë¤Ê¤êÆÀ¤ë¤Î¤«µ¿¤ï¤·¤¤¤Ë¤â¤«¤«¤ï¤é¤º¡¢¥Û¥ë¥â¥óÎÅË¡¤Ï¹­¤¯¹Ô¤ï¤ì¤Æ¤¤¤ë¡£¤½¤Î¸ú²Ì¤Ë¤Ä¤¤¤Æ¤Ï¿¤¯¤ÎÊó¹ð¤¬¤¢¤ë¤¬¡¢²«ÂÎ¥Û¥ë¥â¥ó¤ÎÊä½¼ÎÅË¡¤Ë¤Ä¤¤¤Æ¤Ï¡¢Î®»º¤Î´í¸±¤ò¸º¤é¤¹¤È¸À¤¦¤Ë½¼Ê¬¤Êº¬µò¤Ï¸«¤¤½Ð¤µ¤ì¤Æ¤¤¤Ê¤¤¡£³Î¤«¤Ë¡¢¤¤¤¯¤é¤«¤Ï¸ú²Ì¤¬¤¢¤ë»ö¤ò¼¨º¶¤¹¤ë¥Ç¡¼¥¿¡¼¤Ï¤¢¤ë¤¬¡¢¾ÚÌÀ¤¹¤ë¤Ë¤Ï¤è¤ê¿¤¯¤Î¸¡Æ¤¤¬É¬ÍפǤ¢¤ë¡£

£²¡Ë¹Ã¾õÁ£µ¡Ç½°Û¾ï
¡¡¹Ã¾õÁ£µ¡Ç½°Û¾ï¤Ïή»º¤Î¸¶°ø¤È¤·¤Æ¤·¤Ð¤·¤Ðµó¤²¤é¤ì¤Æ¤¤¤ë¤¬¡¢°Õ³°¤Ê»ö¤Ë¹Ã¾õÁ£¥Û¥ë¥â¥óÃͤΰ۾郎ή»º¤Î¸¶°ø¤Ë¤Ê¤êÆÀ¤ë¤«¤Ë´Ø¤·¤Æ¤Ï¡¢¤½¤ÎľÀÜŪ¤Ê¾Úµò¤Ï̤¤À̵¤¤¤Î¤¬¸½¾õ¤Ç¤¢¤ê¡¢µÕ¤ËºÇ¶áÈÝÄêŪ¤ÊÏÀʸ¤¬Á꼡¤¤¤ÇÊó¹ð¤µ¤ìÃíÌܤòÍá¤Ó¤Æ¤¤¤ë¡£¤·¤«¤·¤Ê¤¬¤é¡¢¥Ð¥»¥É¡¼»áɤ䶶ËÜɤˤߤé¤ì¤ë¹Ã¾õÁ£¤ËÂФ¹¤ë¼«¸Ê¹³ÂΤ¬È¿Éüή»º¤ÎΨ¤Î¾å¾º¤È´Ø·¸¤¹¤ë¤È¤¤¤¦Êó¹ð¤Ï¤¤¤¯¤Ä¤«¤¢¤ë¡£¤½¤ÎÍýͳ¤ÏÉÔÌÀ¤Ç¤¢¤ë¤¬¡¢¼«¸ÊÌȱּÀ´µ¤Ï¤¤¤¯¤Ä¤«¤Î¼«¸Ê¹³ÂΤò¹ç¤ï¤»»ý¤Ä»ö¤¬Îɤ¯¤¢¤ë¤Î¤Ç¡¢¹³¥ê¥ó»é¼Á¹³ÂΤʤɾ¤ÎÇ¥¿±¤ËÂФ·¤Æɸ¶À­¤Î¤¢¤ë¼«¸Ê¹³ÂΤò²ð¤·¤Æή»º¤¬µ¯¤­¤Æ¤¤¤ë²ÄǽÀ­¤ÏÈÝÄê¤Ç¤­¤Ê¤¤¡£

3¡Ë¹â¥×¥í¥é¥¯¥Á¥ó·ì¾É
¡¡¹â¥×¥í¥é¥¯¥Á¥ó·ì¾É¤¬È¿Éüή»º¤Î¸¶°ø¤È¤Ê¤êÆÀ¤ë¤È¤¤¤¦Àâ¤Ïº£¤Î¤È¤³¤í¾ÚÌÀ¤µ¤ì¤Æ¤¤¤Ê¤¤¡£Â¿¤¯¤ÎÏÀʸ¤Ï¡¢Ì¤¼£ÎŤιâ¥×¥í¥é¥¯¥Á¥ó·ì¾É¤Î´µ¼Ô¤Îή»ºÎ¨¤Ï¹â¤¯Ìµ¤¤¤ÈÊó¹ð¤·¤Æ¤¤¤ë¡£Àµ¾ïÇ¥¿±¤Ë¤ª¤¤¤Æ¤â¥×¥í¥é¥¯¥Á¥ó¥ì¥Ù¥ë¤ÏÇ¥¿±½é´ü¤è¤ê¾å¾º¤·¡¢ÈóÇ¥»þ¤Î£±£°ÇܤË㤹¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢¥×¥í¥é¥¯¥Á¥ó¤¬Ä¾ÀÜÇ¥¿±¤ò˸³²¤¹¤ë¤È¤Ï¹Í¤¨¤Ë¤¯¤¤¡£¤·¤«¤·¤Ê¤¬¤é¡¢¸À¤¦¤Þ¤Ç¤â̵¤¯¹â¥×¥í¥é¥¯¥Á¥ó·ì¾É¤Ï̵ÇÓÍñ¤ò°ú¤­µ¯¤³¤·¡¢ÉÔÇ¥¾É¤Î¸¶°ø¤È¤Ê¤êÆÀ¤ë¤Î¤Ç¹â¥×¥í¥é¥¯¥Á¥ó·ì¾É¤È¿ÇÃǤµ¤ì¤¿¾ì¹ç¤Ï¼£ÎŤ¹¤ë¤Ù¤­¤Ç¤¢¤ë»ö¤Ï¸À¤¦¤Þ¤Ç¤â̵¤¤¡£

£²¡¥ÉÔ°é¾É¤ÎʬÌî¤Ë¤ª¤±¤ë¿·¤·¤¤³µÇ°
¡¡ºÇ¶á£±£°Ç¯¤Î¤¢¤¤¤À¤Ë¡¢ÉÔ°é¾É¤Î¿·¤·¤¤¸¶°ø¤ä¼£ÎŤ¬¸«¤¤½Ð¤µ¤ì¤Æ¤­¤¿¡£Â¿¤¯¤ÏÀ¸¿£Ìȱ֡¢·ì±Õ¶Å¸Ç³Ø¤Î¿ÊÊâ¤Ë¤è¤ë¤â¤Î¤Ç¤¢¤ë¡£À¸¿£Ìȱ֤ÎÎΰè¤Ç¤Ï¡¢Th1¤ÈTh2¤Î¥Ð¥é¥ó¥¹¤¬Êø²õ¤¹¤ë»ö¤Ë¤è¤êή»º¤¬µ¯¤­¤ë¤È¤¤¤¦¿·¤·¤¯¡¢¤«¤ÄÌ¥ÎÏŪ¤Ê²¾À⤬ºÇ¶áÃíÌܤµ¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¢·ì±Õ¶Å¸Ç¤ÎÎΰè¤Ç¤Ï¡¢¹³¥ê¥ó»é¼Á¹³Âξɸõ·²¤ò½é¤á¤È¤·¤¿thrombophilia¤ÈÉÔ°é¾É¤Î´Ø·¸¤¬ÌÀ¤é¤«¤Ë¤Ê¤Ã¤Æ¤­¤¿¡£¤³¤³¤Ç¤Ï¡¢¤½¤ì¤é¤Î³µÇ°¤Ë¤Ä¤¤¤Æ¾Ò²ð¤¹¤ë¡£

1¡ËTh1/Th2¥Ð¥é¥ó¥¹
¡¡ÂÛ»ù¤ÏÊìÂΤˤȤäÆȾʬ¤ÏƱ¼ï°Ü¿¢ÊҤǤ¢¤ë¤È¹Í¤¨¤ë¤³¤È¤¬¤Ç¤­¤ë¤¬¡¢Ç¥¿±Ãæ¤ÏµñÀäÈ¿±þ¤¬¤ª¤­¤Æή»º¤Ë¤¤¤¿¤é¤Ê¤¤¤è¤¦¤Ê¡¢¤Ê¤ó¤é¤«¤ÎËɸ浡¹½¤¬Æ¯¤¤¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¶áǯ¡¢ÌȱֳØŪǥ¿±°Ý»ýµ¡¹½¤È¤·¤ÆTh1/Th2¥Ð¥é¥ó¥¹¤¬ÃíÌܤµ¤ì¤Æ¤¤¤ë¡£¤½¤ì¤Ë¤è¤ë¤È¡¢ÊìÂΤ¬ÂÛ»ù¤ò°Ûʪ¤È¤·¤ÆµñÀ䤹¤ë¤³¤È¤Ê¤¯¡¢Ç¥¿±¤¬°Ý»ý¤µ¤ì¤ë¤Î¤ÏºÙ˦À­Ìȱ֤ò»Ê¤ëCD4+ T helper (Th) 1 ºÙ˦µ¡Ç½¤¬Äã²¼¤·¡¢¹³ÂλºÀ¸¤ò»Ê¤ëTh2ºÙ˦µ¡Ç½¤¬Ð¶¿Ê¤¹¤ë¤¿¤á¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£
¡¡½¬´·Î®»º¤ÎÌȱֳØŪ¸¶°ø¤È¤·¤Æ¤Ï¡¢¹³¥ê¥ó»é¼Á¹³ÂΤʤɼ«¸Ê¹³ÂΤˤè¤ë¤â¤Î¤È¡¢Â¡´ï°Ü¿¢¤ÎµñÀäÈ¿±þ¤Ë½à¤¸¤¿µ¡½ø¤¬¹Í¤¨¤é¤ì¡¢¤É¤Á¤é¤âTh1/Th2¥Ð¥é¥ó¥¹¤ÎÇËþ¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤ë¡£¤¹¤Ê¤ï¤Á¡¢Th1/Th2¥Ð¥é¥ó¥¹¤¬Th£±¤ÎÊý¤Ø·¹¤±¤Ð¡¢ÊìÂΤÏÂÛ»ù¤ò°Ûʪ¤È¤·¤Æǧ¼±¤·¡¢µñÀäÈ¿±þ¤¬¤ª¤­¡¢Î®»º¤¹¤ë²ÄǽÀ­¤¬¤¢¤ë¡£¤Þ¤¿¡¢²á¾ê¤ËTh2¤ÎÊý¤Ø·¹¤¯¤È¡¢º£Å٤Ϲ³ÂλºÀ¸¤¬À¹¤ó¤Ë¤Ê¤ê¡¢¹³¥ê¥ó»é¼Á¹³ÂΤʤɤμ«¸Ê¹³ÂΤ¬»ºÀ¸¤µ¤ì¡¢Î®»º¤ò°ú¤­µ¯¤³¤¹²ÄǽÀ­¤¬¤¢¤ë¡£SLE¤Ê¤É¤Î¼«¸ÊÌȱּÀ´µ¤¬¡¢Ç¥¿±¡¦Ê¬ÊÚ¤ò¤­¤Ã¤«¤±¤Ëȯ¾É¤·¤¿¤êÁý°­¤¹¤ë¤Î¤â¡¢Ç¥¿±¤Ë¤è¤êTh1/Th2¥Ð¥é¥ó¥¹¤¬Th2¤ÎÊý¤Ø·¹¤¯»ö¤¬¤­¤Ã¤«¤±¤È¤â¹Í¤¨¤é¤¨¤ë¡£

2¡Ë¥Ê¥Á¥å¥é¥ë¥­¥é¡¼(NK)ºÙ˦¤ÈÉÔ°é¾É
¡¡¤³¤ÎʬÌî¤ÏºÇ¶áÃíÌܤµ¤ì¡¢À¹¤ó¤Ë¸¦µæ¤µ¤ì¤Æ¤¤¤ë¤¬½ôÀâÆþ¤êÍð¤ì¡¢¤½¤ì¤¾¤ì²¾Àâ¤Î°è¤ò¤Ç¤Æ¤¤¤Ê¤¤¡£¼ÂºÝ¤ÎÎ×¾²¤ËNKºÙ˦¤Ë´Ø¤¹¤ë¸¡ºº¡¢¼£ÎŤòƳÆþ¤¹¤ë¤Î¤Ï¸½»þÅÀ¤Ç¤ÏÉÔŬÀڤǤ¢¤ê¡¢¸½¤ËÉÔ°é¾É´µ¼Ô¤Î´Ö¤Ç¤Ïº®Íð¤¬À¸¤¸¤Æ¤¤¤ëÍͤǤ¢¤ë¡£
¡¡Ëö¾¿·ìNKºÙ˦³èÀ­¤ÏÉÔÇ¥¾É¡¢ÉÔ°é¾É´µ¼Ô¤Ë¤ª¤¤¤Æ¹âÃͤǤ¢¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢Ç¥¿±Á°¤ÎNKºÙ˦³èÀ­ÃͤϤ½¤Î¸å¤Îή»º¤òͽÃΤ¹¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¤·¤«¤·¤Ê¤¬¤é¡¢NK³èÀ­¤ÏÀº¿ÀŪ±Æ¶Á¤Ë¤è¤êÊÑÆ°¤¹¤ë¤È¤âÊó¹ð¤µ¤ì¡¢Î®»º¤Î·ë²Ì¤È¤·¤Æ¥¹¥È¥ì¥¹¤Ë¤è¤ê³èÀ­¤¬¾å¾º¤·¤Æ¤¤¤ë²ÄǽÀ­¤âÈÝÄê¤Ç¤­¤Ê¤¤¡£°Ê¾å¤ÎÍͤËËö¾¿·ìNKºÙ˦³èÀ­¤Èή»º¤È¤Î°ø²Ì´Ø·¸¤ÏÉÔÌÀ¤Ç¤¢¤ê¡¢¤Þ¤·¤Æ¼£ÎŤ˴ؤ·¤Æ¤ÏÊó¹ð¤¬¤Ê¤¤¡£
¡¡°ìÊý¤Ç¡¢Ëö¾¿·ì¤È¤Ï°Û¤Ê¤êʬÈç´ü»ÒµÜÆâËì¤äÇ¥¿±½é´üæÍîËì¤Ë¤ÏCD56+/16-¤ÎNKºÙ˦ÍͤΥê¥ó¥Ñµå¡ÊuNKºÙ˦)¤¬ÆÃħŪ¤ËÁý²Ã¤¹¤ë»ö¤¬Êó¹ð¤µ¤ì¡¢¤½¤ÎÌò³ä¤Ë¤Ä¤¤¤Æ¤µ¤Þ¤¶¤Þ¤Ê²¾À⤬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡£ºÇ¶á¤Ç¤Ï¡¢uNKºÙ˦¤ÏÇ¥¿±°Ý»ý¤Ëɬ¿Ü¤Ç¤¢¤ë¤È¤¤¤¦²¾À⤬¿¤¯¤Î»Ù»ý¤ò½¸¤á¤Æ¤¤¤ë¤¬¡¢uNKºÙ˦¤¬Â¸ºß¤·¤Ê¤¤IL-2R¦Ãº¿KO¥Þ¥¦¥¹¤Ç¤âή»º¡¢»ÒµÜÆâÂÛ»ùȯ°éÃٱ䤬À¸¤¸¤Ê¤¤¤È¤¤¤¦¥Ç¡¼¥¿¤¬ºÇ¶áÊó¹ð¤µ¤ì¡¢ÃíÌܤµ¤ì¤Æ¤¤¤ë¡£

3¡Ëthrombophilia¤ÈÉÔ°é¾É
¡¡·ìÀò¾É¤Î¸¶°ø¤È¤Ê¤êÆÀ¤ë´ðÁüÀ´µ¤¬¤¢¤ë¤È¡¢pregnancy loss¤Î¥ê¥¹¥¯¤¬¹â¤¯¤Ê¤ë¤È¤¤¤¦¤Î¤Ï¼þÃΤλö¼Â¤Ç¤¢¤ë2¡Ë3¡Ë¡£È¿ÉüÇ¥¿±½é´üή»º´µ¼Ô¤Ë¤ª¤¤¤Æ·ì±Õ¶Å¸Ç·Ï¤Î¸¡º÷¤ò»Ü¹Ô¤·¤¿¤È¤³¤í¡¢¹³¥ê¥ó»é¼Á¹³ÂΤÈÂ裱£²°ø»Ò·ç˳¾É¤¬2Â縶°ø¤È¤·¤ÆÉ⤫¤Ó¾å¤¬¤Ã¤Æ¤­¤¿2¡Ë7)8)¡£¹³¥ê¥ó»é¼Á¹³ÂΤο¤¯¤Ï½¾Íè¤è¤êÃíÌܤµ¤ì¤Æ¤­¤¿¹³¥«¥ë¥¸¥ª¥ê¥Ô¥ó¹³ÂΤä¥ë¡¼¥×¥¹¥¢¥ó¥Á¥³¥¢¥°¥é¥ó¥È¤è¤ê¤Ï¤à¤·¤í¡¢¥­¥Ë¥Î¡¼¥²¥ó¤òǧ¼±¤¹¤ë¹³¥Õ¥©¥¹¥Õ¥¡¥Á¥¸¥ë¥¨¥¿¥Î¡¼¥ë¥¢¥ß¥ó¹³ÂΤ¬Â¿¤¤4¡Ë-8¡Ë¡£¥­¥Ë¥Î¡¼¥²¥ó¤âÂ裱£²°ø»Ò¤â¡¢¥«¥ê¥¯¥ì¥¤¥ó-¥­¥Ë¥ó·Ï¤ÎÃÁÇò¤Ç¤¢¤ê¡¢ÀþÍϷϤ˽ÅÍפÊÌò³ä¤ò±é¤¸¤Æ¤¤¤ë¡£¤·¤¿¤¬¤Ã¤Æ¡¢¤³¤ì¤é¤ËÂФ¹¤ë¹³ÂΤ¬Â¸ºß¤¹¤ë¤Ê¤É¤·¤Æ³èÀ­¤¬Äã²¼¤¹¤ë¤È¥«¥ê¥¯¥ì¥¤¥ó-¥­¥Ë¥ó·Ï¤ÎÇËþ¤Ë¤è¤ëÀþÍÏ·ÏÄã²¼¤¬À¸¤¸¡¢·ìÀò¤äή»º¤Î¸¶°ø¤ÈÀ®¤êÆÀ¤ë¡£¤Ê¤ª¡¢¹³¥Õ¥©¥¹¥Õ¥¡¥Á¥¸¥ë¥¨¥¿¥Î¡¼¥ë¥¢¥ß¥ó¹³ÂΤϡ¢SRL¤Ç¬Äê²Äǽ¤Ç¤¢¤ë¡£
¡¡Ç¥¿±¸å´ü¤Ë»ÒµÜÆâÂÛ»ù»àË´¤òµ¯¤³¤¹¥¿¥¤¥×¤ÎÉÔ°é¾É·²¤Ç·ì±Õ¶Å¸Ç·Ï¤ò¸¡º÷¤¹¤ë¤È¡¢¥×¥í¥Æ¥¤¥óS·ç˳¡¢¹³¥«¥ë¥¸¥ª¥ê¥Ô¥ó¹³ÂÎÂ裵°ø»Ò Leiden mutation¤Ê¤É¤¬risk factor¤È¤·¤Æµó¤²¤é¤ì¤¿3¡Ë¡£¤Þ¤¿¡¢ºÇ¶á¹â¥Û¥â¥·¥¹¥Æ¥¤¥ó·ì¾É¤È·ìÀò¾É¤Î´Ø·¸¤¬ÃíÌܤµ¤ì¤Æ¤ª¤ê¡¢¤½¤Î¸¶°ø¤Î°ì¤Ä¤È¤·¤Æmethylenetetrahydrofolate reductase(MTHFR) gene¤ÎC677T mutation¤¬µó¤²¤é¤ì¤Æ¤¤¤ë¤¬¡¢¤³¤ÎC677T mutation¤È¾åµ­¤Îrisk factor¤Î¹çÊ»¾ÉÎã¤â¿¤¯¡¢Ç¥¿±Ãæ¤ËÍÕ»À¤ÎɬÍ×À­¤¬Áý¤¹¤³¤È¤â¤¢¤Ã¤Æ¡¢¤½¤Î¤è¤¦¤Ê¾ÉÎã¤Ç¤ÏÍÕ»À¤Î·Ð¸ýÀݼ褬´«¤á¤é¤ì¤Æ¤¤¤ë3¡Ë¡£

£³¡¥ÌȱÖÎÅË¡¤Ë¤Ä¤¤¤Æ¤ÎºÇ¶á¤Î¹Í¤¨Êý
¡¡ÂÛ»ù¤ÏÊìÂΤˤȤäÆȾʬ¤ÏƱ¼ï°Ü¿¢ÊҤǤ¢¤ë¤È¹Í¤¨¤ë¤³¤È¤¬¤Ç¤­¤ë¤¬¡¢Ç¥¿±Ãæ¤ÏµñÀäÈ¿±þ¤¬¤ª¤­¤Æή»º¤Ë¤¤¤¿¤é¤Ê¤¤¤è¤¦¤Ê¡¢¤Ê¤ó¤é¤«¤ÎËɸ浡¹½¤¬Æ¯¤¤¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤ë¡£¤½¤·¤Æ¡¢¤³¤ÎÇ¥¿±°Ý»ýµ¡¹½¤Î¥Ð¥é¥ó¥¹¤¬Êø¤ì¡¢Î®»º¤Ë¤¤¤¿¤ë¤è¤¦¤Ê¥¿¥¤¥×¤ÎÉÔ°é¾É¤¬Â¸ºß¤¹¤ë²ÄǽÀ­¤¬¼¨º¶¤µ¤ì¤Æ¤­¤¿¡£¤¹¤Ê¤ï¤Á¡¢Th1/Th2¥Ð¥é¥ó¥¹¤¬Th1¤Ë·¹¤¤¤¿¾õÂÖ¤ÈÁÛÄꤵ¤ì¤ë¡£¤·¤«¤·¤Ê¤¬¤é¡¢ÂÛÈפȤ¤¤¦²ò˶³ØŪ¾ãÊɤθºß¤äÆüì¤ÊÆâʬÈç´Ä¶­¡¢¥µ¥¤¥È¥«¥¤¥ó¤Î´ØÍ¿¤Ê¤É¡¢Ç¥¿±¤Ë¤Ï¡´ï°Ü¿¢¤È¤Ï°Û¤Ê¤ë¥Õ¥¡¥¯¥¿¡¼¤â¿¤¯¡¢Â¡´ï°Ü¿¢¤ÈƱÍͤˤ¢¤Ä¤«¤¦¤³¤È¤Ï¤Ç¤­¤Ê¤¤¡£Â¡´ï°Ü¿¢¤Ë¤ª¤¤¤Æ¡¢°Ü¿¢¤µ¤ì¤¿Â¡´ï¤¬µñÀ䤵¤ì¤º¤ËÀ¸Ã夹¤ë¤Ë¤Ï¡¢Çò·ìµå¤Î·ì±Õ·¿¤Ç¤¢¤ëHLA¤ÎŬ¹ç¤¬½ÅÍפǤ¢¤ë¡£Æ±Íͤˡ¢Ç¥¿±°Ý»ý¤Ë¤ª¤¤¤Æ¤âÉ×ÉØ´Ö¤ÎHLA¤Î°ìÃס¢ÉÔ°ìÃפ¬½ÅÍפʤΤǤϤʤ¤¤«¤È¤¤¤¦²¾À⤬°ìÀ¤¤òÉ÷óÓ¤·¡¢É×ÉØ´Ö¤ÎHLA¤ÎŬ¹ç¿ô¤ÇÁêÀ­¤¬Îɤ¤¤È¤«°­¤¤¤È¤«È½Äꤷ¡¢ÁêÀ­¤Î°­¤¤¾ÉÎã¤Ë¤ÏÉ×¥ê¥ó¥Ñµå¤òÍѤ¤¤¿ÌȱÖÎÅË¡¤¬Í­¸ú¤Ç¤¢¤ë¤È¤µ¤ì¤¿¡£¤·¤«¤·¤Ê¤¬¤é¡¢¤½¤Î¸å¤Î¸¡Æ¤¤Ë¤è¤ê¡¢º£¤Ç¤ÏHLA¤ÎŬ¹ç¿ô¤Èή»º¤È¤ÎÁê´Ø´Ø·¸¤ÏÈÝÄꤵ¤ì¤¿¡£º£¤Ç¤ÏÌȱÖÎÅË¡¤Ï¡¢½ô¸¡ºº»Ü¹Ô¤·¤Æ¤â°Û¾ï¤Î¸«¤¤½Ð¤µ¤ì¤Ê¤¤¸¶°øÉÔÌÀ½¬´·Î®»º¡Ê£²²ó¤Îή»º´û±ý¤ÏŬ±þ¤È¤Ê¤é¤Ê¤¤¡Ë¤Ç¡¢¹³³Ë¹³ÂΤ乳¥ê¥ó»é¼Á¹³ÂΤʤɤμ«¸Ê¹³ÂΤò»ý¤¿¤Ê¤¤¾ÉÎã¤òÂоݤˡ¢Å¬±þ¤ò¿µ½Å¤Ë¸¡Æ¤¤·¤¿¤¦¤¨¤Ç»Ü¹Ô¤µ¤ì¤Æ¤¤¤ë¡£ºîÍѵ¡½ø¤È¤·¤Æ¤Ï¡¢Th1/Th2¥Ð¥é¥ó¥¹¤òTh2¤ÎÊý¤ØÀ§Àµ¤¹¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¤¬¡¢ÈÝÄêŪ¤ÊÏÀʸ¤â¤¢¤ê¡¢Ì¤¤ÀºîÍѵ¡½ø¤ÏÉÔÌÀ¤Ç¤¢¤ë¡£¤Þ¤¿¡¢ÉûºîÍѤâÊó¹ð¤µ¤ì¤Æ¤¤¤ë¤Î¤Ç¡¢°Â°×¤ËÌȱÖÎÅË¡¤òÍðÍѤ¹¤ë¤³¤È¤Ï¿µ¤à¤Ù¤­¤Ç¤¢¤ë¡£

¤ª¤ï¤ê¤Ë
¡¡°Ê¾å¡¢ÉÔ°é¾É¤ÎºÇ¶á¤Î¿ÊÊâ¤Ë¤Ä¤¤¤Æ³µÀ⤷¤¿¡£¸À¤¦¤Þ¤Ç¤â̵¤¯ÉÔÇ¥¾É¤È¤ÏÁ´¤¯°Û¤Ê¤ëʬÌî¤Ç¤¢¤ê¡¢ÀìÌçŪÃ챤òÍפ¹¤ë¡£ËܹƤ¬ÉÔ°é¾É¤ÎʬÌî¤ÎÍý²ò¤Ë¾¯¤·¤Ç¤â¤ªÌò¤ËΩ¤Æ¤ì¤Ð¹¬¤¤¤Ç¤¢¤ë¡£

»²¹Íʸ¸¥
1)Plachot M et al. Are clinical and biological IVF parameters correlated with chromosomal disorders in early life: a multicentric study. Hum Reprod,3:627-635,1988
2)Gris JC et al. Prospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. Thromb Haemost, 77: 1096-103, 1997.
3)Gris JC et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent. Thromb Haemost, 81:891-99,1999.
4) Sugi T and McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86:3083-9,1995
5) Sugi T and McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 76:354-60,1996
6) Sugi T et al. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 71: 1060-5,1999
7) Sugi T and Makino T. Plasma contact system, Kallikrein-kinin system and antiphospholipid-protein antibodies in thrombosis and pregnancy. J Reprod Immunol 47: 169-184, 2000
8) Sugi T and Makino T. Autoantibodies to contact proteins in patients with recurrent pregnancy losses. J Reprod Immunol (in press).

| chezsmile | °å³ØŪ¥¢¥×¥í¡¼¥Á | 21:24 | comments(1) | - |

¥³¥á¥ó¥È
¤³¤Î¤è¤¦¤Ê½ÅÍפʥȥԥ寤ˤĤ¤¤Æ¼è¤ê¾å¤²¤Æ¤¤¤¿¤À¤­¡¢¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤¹¡£¤³¤Î¤è¤¦¤Ê¥³¥ó¥Æ¥ó¥Ä¤¬¤â¤Ã¤ÈɬÍפǤ¹¡£
| www.twohillsseptic.ca | 2024/03/05 1:09 PM |
¥³¥á¥ó¥È¤¹¤ë









Calendar
SUNMONTUEWEDTHUFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
<< November 2024 >>

RECOMMEND
¥É¥ô¥©¥ë¥¶¡¼¥¯¡¦¥¤¥ó¡¦¥×¥é¥Ï
¥É¥ô¥©¥ë¥¶¡¼¥¯¡¦¥¤¥ó¡¦¥×¥é¥Ï

¤³¤Î¥¢¥ë¥Ð¥à¤Ë½ê¼ý¤Î
¤ï¤¬Ê줬¶µ¤¨µë¤¤¤·²Î
ÎÞ¤¬½Ð¤ë¤Û¤É´¶Æ°¤·¤Þ¤¹¡£

RECENT COMMENTS

CATEGORIES

ARCHIVES

LINKS

PROFILE

OTHERS

PageTop